This retrospective cohort study was conducted during November 2013-November 2015 among patients who met the inclusion criteria and were admitted to Razi hospital. This study was approved by the ethic committee of Razi hospital (registration number, 96-01-30-34288, approved by the Vice Chancellor for Research of Tehran University of Medical Sciences). Informed consents were also obtained from the patients.
Before the operation, a 22-gauge intravenous cannula was placed in the patient's forearm for continuous infusion of Ringer’s solution. Oxygen was continuously administered to patients through a nasal probe. Heart rate, electrocardiogram (EKG), and oxygen saturation (using a digital probe) were continuously monitored. Blood pressure was also measured automatically every 3 minutes, using an automatic monitoring device. Mild to moderate sedation was practiced to facilitate these procedures.
The sedation protocol was as follows for patients aged 10 - 65 years (except children undergoing general anesthesia): midazolam (1 - 2 mg), fentanyl (1 - 1.5 µ/kg), propofol (0.5 - 1 mg/kg), and ketamine (0 - 0.5 mg/kg). For patients above 65 years, the sedation protocol was as follows: midazolam (1 mg), fentanyl (0 - 1 µ/kg), and ketamine (0 - 0.5 mg/kg). Lidocaine 1% - 2%, along with adrenaline (1:100,000), was administered topically, besides anesthetizing the tumor resection site. In hypertensive patients, the solution was prepared with adrenaline (1:200,000). Also, hypertensive patients were treated with labetalol, hydralazine, or nitroglycerin infusion.
Symptomatic bradycardia was defined as heart rate below 49 beats per minute and systolic blood pressure below 85 mmHg. Intervention was initiated by inotropic and chronotropic drugs. Two protocols were designed for restoring hemodynamic parameters in patients with symptomatic bradycardia. According to the anesthesiologist's decision, the patients were enrolled in atropine or ephedrine group.
In the atropine group, 0.5 mg of atropine was administrated as the first-line drug, and if no clinical responses were observed within 45 seconds, 10 mg of ephedrine was injected to restore hemodynamic parameters. If the response was unacceptable, another dose of ephedrine (10 mg) was administered. On the other hand, in the ephedrine group, ephedrine (10 mg) was injected as the first-line drug for the management of symptomatic bradycardia; if no clinical responses were observed in 45 seconds, another dose of ephedrine was administered.
For intensive symptomatic bradycardia (systolic blood pressure < 70 mmHg and heart rate < 49/min), another management protocol was designed. The efficacy of each drug (atropine 0.5 mg and ephedrine 10 mg) was determined by dividing the number of patients, who required only 1 dose of the drug for a significant rise in their hemodynamic parameters (heart rate > 55/min, systolic blood pressure > 90 mmHg), by the number of patients in that group.
Statistical tests were performed, using SPSS version 13 for Windows. The results are reported as absolute values and mean ± SD. Also, nominal variables were analyzed by Chi square test. P value less than 0.05 was considered statistically significant.